Armistice Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Armistice Capital, LLC

  • $6.02 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018
SELL
$5.89 - $7.78 $10.8 Million - $14.3 Million
-1,836,000 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$6.76 - $11.7 $1 Million - $1.73 Million
148,000 Added 8.77%
1,836,000 $13.4 Million
Q3 2017

Nov 14, 2017
BUY
$8.35 - $10.5 $14.1 Million - $17.7 Million
1,688,000
1,688,000 $17.7 Million

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email